Cutting edge approaches toward novel and cross-protective influenza vaccines

Development of Novel Vaccines: Skills, Knowledge and Translational Technologies

Volumn , Issue , 2012, Pages 205-232

  Roose, Kenny ^a   Schotsaert, Michael ^a   El Bakkouri, Karim ^a   Schepens, Bert ^a   Fiers, Walter ^a   Saelens, Xavier ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874076843     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-0709-6_9     Document Type: Chapter

References (172)

1. Ameiss K et al (2010) Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. Vaccine 28(41): 6704-6713
2. Assarsson E et al (2008) Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 82(24):12241-12251
3. Beerli RR et al (2009) Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against Influenza A M2 protein. Virol J 6:224
4. Berkhoff EG et al (2005) Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol 79(17):11239-11246
5. Bessa J et al (2008) Efficient induction of mucosal and systemic immune responses by virus like particles administered intranasally: implications for vaccine design. Eur J Immunol 38(1): 114-126
6. Black RA et al (1993) Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 74(1):143
7. Bodewes R et al (2009) Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One 4(5):e5538
8. Bodewes R et al (2011) Vaccination against seasonal influenza A/H3N2 reduces the induction of heterosubtypic immunity against influenza A/H5N1 in ferrets. J Virol 85(6):2695-2702
9. Bommakanti G et al (2010) Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 107(31): 13701
10. Boon AC et al (2004) Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol 172(4):2453-2460
11. Bron R et al (1993) Role of the M2 protein in influenza virus membrane fusion: effects of amantadine and monensin on fusion kinetics. Virology 195(2):808-811
12. Brown DM et al (2006) CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177(5):2888-2898
13. Caton AJ, Gerhard W (1992) The diversity of the CD4+ T cell response in influenza. Semin Immunol 4(2):85-90
14. Chen BJ et al (2008) The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J Virol 82(20):10059
15. Chen GL et al (2011) Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc Natl Acad Sci USA 108(3):1140-1145
16. Corti D et al (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120(5):1663
17. De Filette M et al (2005) Universal influenza A vaccine: optimization of M2-based constructs. Virology 337(1):149-161
18. De Filette M et al (2008) An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283(17):11382
19. De Filette M et al (2011) Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective. J Gen Virol 92(2):301
20. Denis J et al (2008) Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26(27-28):3395-3403
21. Doherty PC et al (2006) Influenza and the challenge for immunology. Nat Immunol 7(5):449
22. Ebrahimi SM, Tebianian M (2010) Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 42(1):1-8
23. Ebrahimi SM et al (2010) Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris. Protein Expr Purif 70(1):7-12
24. Eichelberger Metal(1991) Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med 174(4):875
25. Ekiert DC et al (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924):246
26. El Bakkouri K et al (2010) Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186(2):1022-1031
27. El Bakkouri K et al (2011) Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186(2):1022
28. Eliasson DG et al (2008) CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26(9):1243-1252
29. Epstein SL (2006) Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193(1): 49-53
30. Fan J et al (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22(23-24):2993-3003
31. Fedson DS (1996) Evaluating the impact of influenza vaccination. A North American perspective. Pharmacoeconomics 9:54
32. Feng JQ et al (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3(1):102
33. Fiers W et al (2009) M2e-based universal influenza A vaccine. Vaccine 27(45):6280
34. Fouchier RAM et al (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79(5):2814
35. Frace AM et al (1999) Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17(18):2237-2244
36. Friesen RHE et al (2010) New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 5(2):e9106
37. Fu TM et al (2009a) Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385(1):218
38. Fu TM et al (2009b) Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27(9): 1440
39. Furuse Y et al (2009) Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis. Virol J 6:67
40. Gannage M et al (2009) Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe 6(4):367-380
41. Ge X et al (2010) Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 84(7):3312-3319
42. Gerhard W et al (1981) Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290(5808):713-717
43. Grandea AG et al (2010) Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci USA 107(28):12658
44. Grantham ML et al (2009) Palmitoylation of the influenza A virus M2 protein is not required for virus replication in vitro but contributes to virus virulence. J Virol 83(17):8655
45. Graves PN et al (1983) Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 126(1):106-116
46. Green N et al (1982) Immunogenic structure of the influenza virus hemagglutinin. Cell 28(3): 477-487
47. Greenbaum JA et al (2009) Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 106(48):20365-20370
48. Guan Z et al (2010) Interaction of Hsp40 with influenza virus M2 protein: implications for PKR signaling pathway. Protein Cell 1(10):944-955
49. Haanen J et al (1999) Selective expansion of cross-reactive Cd8+ memory T cells by viral variants. J Exp Med 190(9):1319
50. Hancock K et al (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361(20):1945
51. Harbury PB et al (1993) A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262(5138):1401
52. Harris A et al (2006) Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci USA 103(50):19123
53. Hobson D et al (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg 70(4):767
54. Holsinger LJ, Lamb RA (1991) Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 183(1):32
55. Holsinger LJ et al (1994) Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 68(3):1551
56. Holsinger LJ et al (1995) Analysis of the posttranslational modifications of the influenza virus M2 protein. J Virol 69(2):1219
57. Huleatt JW et al (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26(2):201-214
58. Ikonen N et al (2010) High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 15(5):19478
59. Iwatsuki-Horimoto K et al (2006) The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J Virol 80(11):5233
60. Jegerlehner A et al (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172(9):5598
61. Johansson BE, Kilbourne ED (1993) Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 67(10):5721
62. Johansson BE, Kilbourne ED (1996) Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology 225(1):136
63. Johansson BE, Moran TM, Kilbourne ED (1987) Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci USA 84(19):6869
64. Kashyap AK et al (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105(16):5986
65. Khurana S et al (2009) Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med 6(4): e1000049
66. Kilbourne ED, Schulman JL (1965) The induction of broadened (multitypic) immunity with doubly antigenic influenza virus recombinants. Trans Assoc Am Physicians 78:323
67. Kitikoon P, Strait EL, Thacker EL (2008) The antibody responses to swine influenza virus (SIV) recombinant matrix 1 (rM1), matrix 2 (M2), and hemagglutinin (HA) proteins in pigs with different SIV exposure. Vet Microbiol 126(1—3):51
68. Kitikoon P et al (2009) Swine influenza matrix 2 (M2) protein contributes to protection against infection with different H1 swine influenza virus (SIV) isolates. Vaccine 28(2):523-531
69. Knossow M, Skehel JJ (2006) Variation and infectivity neutralization in influenza. Immunology 119(1):1-7
70. Kovacsovics-Bankowski M et al (1993) Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90(11):4942-4946
71. Kreijtz JH et al (2007) Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25(4):612-620
72. Kreijtz JH et al (2009) Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27(36):4983-4989
73. Kresse H, Rovini H (2009) Influenza vaccine market dynamics. Nat Rev Drug Discov 8(11): 841-842
74. Krystal M et al (1982) Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc Natl Acad Sci USA 79(15):4800
75. Lamb RA, Choppin PW (1981) Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 112(2):729-737
76. Lamb RA, Zebedee SL, Richardson CD (1985) Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40(3):627-633
77. Laurie KL et al (2010) Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 202(7): 1011-1020
78. Lee LY et al (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118(10):3478-3490
79. Leser GP, Lamb RA (2005) Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 342(2): 215-227
80. Liu W, Zou P, Chen YH (2004) Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 93(2-3):131
81. Liu W et al (2005) Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 7(2):171-177
82. Lowin B et al (1994) Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370(6491):650-652
83. Ludwig C, Wagner R (2007) Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 18(6):537-545
84. Lukacher AE, Braciale VL, Braciale TJ (1984) In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 160(3):814
85. Lundegaard C, Nielsen M, Lund O (2006) The validity of predicted T-cell epitopes. Trends Biotechnol 24(12):537-538
86. Mackenzie CD, Taylor PM, Askonas BA (1989) Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells. Immunology 67(3):375
87. Marshall D et al (1999) TH cells primed during influenza virus infection provide help for qualitatively distinct antibody responses to subsequent immunization. J Immunol 163(9):4673-4682
88. Martinez O, Tsibane T, Basler CF (2009) Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int Rev Immunol 28(1-2):69-92
89. McElhaney JE et al (2006) T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176(10):6333-6339
90. McMichael AJ et al (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309(1):13-17
91. McVernon J et al (2011) Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study. Influenza Other Respi Viruses 5(1):7-11
92. Mi SF, Li Y, Yan JH (2010) Na+/K+-ATPase 1 subunit interacts with M2 proteins of influenza A and B viruses and affects the virus replication. Sci China Life Sci 53:1098-1105
93. Miller E et al (2010) Incidence of 2009 pandemic influenza A H1N1 infection in England: a crosssectional serological study. Lancet 375(9720):1100-1108
94. Min Jou W et al (1980) Complete structure of the hemagglutinin gene from the human influenza A/Victoria/3/75 (H3N2) strain as determined from cloned DNA. Cell 19(3):683
95. Misplon JA et al (2010) Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 28(36):5817-5827
96. Moise L, De Groot AS (2006) Putting immunoinformatics to the test. Nat Biotechnol 24(7): 791-792
97. Moris P et al (2010) H5N1 influenza vaccine formulated with AS03 A induces strong crossreactive and polyfunctional CD4 T-cell responses. J Clin Immunol 31(3):443-54
98. Moutaftsi M et al (2006) A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol 24(7):817-819
99. Mozdzanowska K et al (2003) Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21(19-20):2616-2626
100. Mozdzanowska K et al (2007) Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 4(1):118
101. Nayak B et al (2010) Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol 84(5):2408
102. Neirynck S et al (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5(10):1157-1163
103. Nemchinov LG, Natilla A (2007) Transient expression of the ectodomain of matrix protein 2 (M2e) of avian influenza A virus in plants. Protein Expr Purif 56(2):153-159
104. Okada A, Miura T, Takeuchi H (2001) Protonation of histidine and histidine-tryptophan interaction in the activation of the M2 Ion channel from influenza A virus. Biochemistry 40(20): 6053-6060
105. Okuno Y et al (1990) Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 28(6):1308
106. Okuno Y et al (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67(5):2552
107. Okuno Y et al (1994) Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 68(1):517
108. Park EK et al (1998) The M2 ectodomain is important for its incorporation into influenza A virions. J Virol 72(3):2449
109. Pejoski D et al (2010) A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol 88(5):605-611
110. Peters B et al (2005) The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 3(3):e91
111. Riedl K et al (2008) The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 26(27-28):3461
112. Rimmelzwaan GF et al (2000) A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19(9-10):1180
113. Rimmelzwaan GF et al (2004) Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res 103(1-2):97-100
114. Rossman JS et al (2010a) Influenza virus M2 ion channel protein is necessary for filamentous virion formation. J Virol 84(10):5078
115. Rossman JS et al (2010b) Influenza virus M2 protein mediates ESCRT-independent membrane scission. Cell 142(6):902-913
116. Russell CJ, Webster RG (2005) The genesis of a pandemic influenza virus. Cell 123(3):368
117. Sagawa H et al (1996) The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol 77(7):1483
118. cherle PA, Gerhard W (1988) Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo. Proc Natl Acad Sci USA 85(12):4446
119. Scherle PA, Palladino G, Gerhard W (1992) Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J Immunol 148(1):212
120. Schotsaert M et al (2009) Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8(4):499
121. Schuurhuis DH et al (2002) Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 168(5):2240-2246
122. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69(1):531-569
123. Skehel JJ et al (1980) Studies on the Structure of the Haemagglutinin. Phil Trans Roy Soc Lond B Biol Sci 288(1029):335-339
124. Slepushkin VA et al (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13(15):1399-1402
125. Smirnov YA et al (2000) Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol 145(8):1733-1741
126. Song JM et al (2011a) Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci USA 108(2):757-761
127. Song JM et al (2011b) Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6(1):1921-1925
128. Steel J et al (2010a) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1(1):e00018
129. Steel J et al (2010b) Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J Virol 84(1):21-26
130. Straight TM et al (2008) Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats. Virol J 5:44
131. Subbramanian RA et al (2010) Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. Hum Immunol 71(10):957-963
132. Sui J et al (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16(3):265-273
133. Takeuchi K, Lamb RA (1994) Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport. J Virol 68(2):911
134. Teijaro JR et al (2010) Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 84(18):9217-9226
135. Throsby M et al (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3(12):3942
136. Tissot AC et al (2010) Versatile virus-like particle carrier for epitope based vaccines. PLoS One 5(3):54-60
137. Tompkins SM et al (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13(3):426
138. Topham DJ, Tripp RA, Doherty PC (1997) CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159(11):5197-5200
139. Treanor JJ et al (1990) Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64(3):1375
140. Tu W et al (2010) Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 84(13):6527-6535
141. Ulmer JB et al (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259(5102):1745-1749
142. Vareckova E et al (2003) Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies. Arch Virol 148(3):469-486
143. Venkataraman P, Lamb RA, Pinto LH (2005) Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza A virus. J Biol Chem 280(22):21463
144. Verhoeyen M et al (1980) Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75. Nature 286(5775):771
145. Vita R et al (2009) The immune epitope database 2.0. Nucleic Acids Res 38:D854-D862
146. Wack A et al (2008) Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26(4):552
147. Wang R et al (2008) Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antivir Res 80(2):168
148. Wang Y et al (2009) Monoclonal antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of influenza A viruses in MDCK cells. Biochem Biophys Res Commun 385(1):118
149. Wang TT et al (2010a) Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6:e100796
150. Wang TT et al (2010b) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. ProcNatl Acad Sci USA 107(44):18979
151. Watanabe T et al (2001) Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. J Virol 75(12):5656
152. Watanabe S, Watanabe T, Kawaoka Y (2009) Influenza A virus lacking M2 protein as a live attenuated vaccine. J Virol 83(11):5947
153. Waterfield MD et al (1979) Structure of the haemagglutinin of influenza virus. Br Med Bull 35(1)
154. Webster RG et al (1992) Evolution and ecology of influenza A viruses. Microbiol Mol Biol Rev 56(1):152
155. Wharton SA et al (1994) Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J Gen Virol 75(4):945
156. White J, Kartenbeck J, Helenius A (1982) Membrane fusion activity of influenza virus. EMBO J 1(2):217
157. WHO (2011) http://www.who.int/mediacentre/factsheets/fs211/en/index.html
158. Wiley DC, Skehel JJ (1987) The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 56(1):365-394
159. Wiley DC, Wilson IA, Skehel JJ (1981) Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289(5796):373
160. Wrammert J et al (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208(1):181
161. Wu F et al (2007) Characterization of immunity induced by M2e of influenza virus. Vaccine 25(52):8868-8873
162. Wu F et al (2009) Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. Vaccine 27(43):6095
163. Yap KL, Ada GL, McKenzie IF (1978) Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273(5659):238-239
164. Yetter RA, Barber WH, Small PA Jr (1980) Heterotypic immunity to influenza in ferrets. Infect Immun 29(2):650
165. Zebedee SL, Lamb RA (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62(8):2762
166. Zhang GG et al (2009) Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route. Vet Res Commun 33(7):735
167. Zhang Z et al (2010) Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus. Virol J 7(1):89
168. Zhao G et al (2010a) Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 28(44):7233-7240
169. Zhao G et al (2010b) An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J 7:151
170. Zhao G et al (2010c) An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 7:9
171. Zharikova D et al (2005) Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 79(11):6644
172. Zou P, Liu W, Chen YH (2005) The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int Immunopharmacol 5(4):631